Numerous studies have, however, demonstrated that IgM antibodies provide extended tumour immunosurveillance as well as anti-tumour cytotoxic activity in other organisms4, 5, 6, 7, 8, 9, and IgM antibody therapy has been shown to reduce neuroblastoma and melanoma in humans10, 11. The gene discussed is CD40LG; the disease is neuroblastoma.